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or p16 negative cells, indicating a differential role of p16 
protein expression depending on its localization. Strikingly, 
cells expressing nuclear p16 (p16-NLS) -although showing a 
similar level of gH2AX induction- were characterized with 
lower number RAD51 foci formation compared to cells 
expressing cytoplasmic p16 (p16-NES), suggesting an impaired 
HRR. 
 
Conclusion: Cellular p16 localization is an important factor 
for stratification of HNSCC patients with nuclear p16 
expression showing a superior predictive value for 
radiotherapy response. 
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Purpose or Objective: To retrospectively assess the 
prognostic value of the potential biomarkers, i.e. chemokine 
receptor CXCR4, its ligand CXCL12 (SDF1), and nuclear EGFR 
expression in a cohort of 201 patients with locally advanced 
HNSCC. Patients were treated between 2005 and 2011 in 8 
German cancer centers, as part of a multicenter biomarker 
study of the German Cancer Consortium Radiation Oncology 
Group (DKTK-ROG). Experimental data and first clinical 
observations suggest that activation of CXCR4 and SDF1 
signaling pathway and nuclear location of EGFR are 
implicated in tumour cell proliferation, cellular survival, 
tumour progression, worse overall survival, metastasis and 
enhanced treatment resistance in different tumour types. 
 
Material and Methods: Patients with locally advanced SCC of 
the oral cavity, oropharynx and hypopharynx were treated 
with resection and adjuvant RT and Cisplatin-based CT. 
Tissue micro-arrays (TMAs) were generated from surgical 
specimens and evaluated for the expression of the 
biomarkers by immunofluorescence with a semi-quantative 
method, based on their cellular location (membranous, 
intracellular, nuclear), extent of expression on TMA area and 
staining intensity. The results of the biomarker analysis along 
with the clinical parameters were then correlated with the 
clinical outcome. 
 
Results: In univariate analysis, tumours with either SDF1 or 
CXCR4 intracellular overexpression displayed a significant 
negative correlation with loco-regional control (LCR) (HR: 
2.52, p=0.01 and HR: 1.96, p=0.05 respectively). No 
correlation was observed for the nuclear expression of EGFR 
(HR: 0.85, p= 0.67), membranous expression of SDF1 (p=0.73) 
or CXCR4 (p=0.38). Tumours with intracellular co-expression 
of both SDF1 and CXCR4 were significantly correlated with 
poor LRC (HR: 2.72, p=0.01). Previously published data from 
the same cohort, showed that absence of p16 (negative HPV 
status) was correlating with poor LRC. Importantly, increased 
expression of SDF1 or co-expression with CXCR4 could 
identify a group of patients with significantly worse outcome 
within the HPV negative group (p=0.01). Multivariate cox 
regression analysis including HPV status, tumour localisation, 
tumour volume and the respective biomarkers indicated a 
significant independent role of SDF1 (HR: 2.20, p=0.04) and 
co-expression with CXCR4 (HR: 2.19, p=0.05) on LRC. 
 
Conclusion: In summary, pre-treatment overexpression of 
CXCR4/SDF1 is an independent negative prognostic factor for 
the outcome of patients with locally advanced HNSCC who 
receive surgery and standard RT-CT. Further investigation in 
a cohort of patient receiving primary RT-CT and a 
prospective validation study is currently ongoing. 
SDF1/CXCR4 appears to be a promising biomarker for 
treatment individualization, in particular in HPV negative 
advanced HNSCC patients and supports strategies using 
drugable targets against this pathway to enhance efficacy of 
standard treatment. 
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